RISK6, a 6-gene transcriptomic signature of TB disease risk, diagnosis and treatment response
Top Cited Papers
Open Access
- 25 May 2020
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 10 (1) , 1-21
Abstract
Improved tuberculosis diagnostics and tools for monitoring treatment response are urgently needed. We developed a robust and simple, PCR-based host-blood transcriptomic signature, RISK6, for multiple applications: identifying individuals at risk of incident disease, as a screening test for subclinical or clinical tuberculosis, and for monitoring tuberculosis treatment. RISK6 utility was validated by blind prediction using quantitative real-time (qRT) PCR in seven independent cohorts. Prognostic performance significantly exceeded that of previous signatures discovered in the same cohort. Performance for diagnosing subclinical and clinical disease in HIV-uninfected and HIV-infected persons, assessed by area under the receiver-operating characteristic curve, exceeded 85%. As a screening test for tuberculosis, the sensitivity at 90% specificity met or approached the benchmarks set out in World Health Organization target product profiles for non-sputum-based tests. RISK6 scores correlated with lung immunopathology activity, measured by positron emission tomography, and tracked treatment response, demonstrating utility as treatment response biomarker, while predicting treatment failure prior to treatment initiation. Performance of the test in capillary blood samples collected by finger-prick was noninferior to venous blood collected in PAXgene tubes. These results support incorporation of RISK6 into rapid, capillary blood-based point-of-care PCR devices for prospective assessment in field studies.Keywords
All Related Versions
Funding Information
- U.S. Department of Health & Human Services | NIH | Fogarty International Center (D43 TW010559)
- Margaret MaNamara Educational grant
- South African Medical Research Council
- Tuberculosis Research Unit Network
- Bill and Melinda Gates Foundation (OPP1023483, OPP1065330)
- Bill and Melinda Gates Foundation
- Division of Intramural Research (U01-AI069923)
This publication has 44 references indexed in Scilit:
- The Dynamics of QuantiFERON-TB Gold In-Tube Conversion and Reversion in a Cohort of South African AdolescentsAmerican Journal of Respiratory and Critical Care Medicine, 2015
- A comprehensive assessment of RNA-seq accuracy, reproducibility and information content by the Sequencing Quality Control ConsortiumNature Biotechnology, 2014
- Virulence and Pathogenesis of HIV-1 Infection: An Evolutionary PerspectiveScience, 2014
- Systemic Effects of Inflammation on Health during Chronic HIV InfectionImmunity, 2013
- Immune activation and HIV persistence: implications for curative approaches to HIV infectionImmunological Reviews, 2013
- Detectable Changes in The Blood Transcriptome Are Present after Two Weeks of Antituberculosis TherapyPLOS ONE, 2012
- Distinct Phases of Blood Gene Expression Pattern Through Tuberculosis Treatment Reflect Modulation of the Humoral Immune ResponseThe Journal of Infectious Diseases, 2012
- Tackling the widespread and critical impact of batch effects in high-throughput dataNature Reviews Genetics, 2010
- Increased Interferon Alpha Expression in Circulating Plasmacytoid Dendritic Cells of HIV-1-Infected PatientsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2008
- HIV-1 immunopathogenesis: How good interferon turns badClinical Immunology, 2007